Figure 1A ADV ADV+LAM 0 2 4 6 8 HBV DNA (Log IU/mL) 0 100 200 300 400 500 ALT (IU/mL) A Months of therapy M0M7M14M21M28M35M42M48M56.

Slides:



Advertisements
Similar presentations
Treatment appropriate Normal or minimal hepatitis Chronic hepatitis Normal or inactive hepatitis Progressive fibrosis Cirrhosis HCC HBeAg Anti-HBe HBV.
Advertisements

Anna LOK. Management of Antiviral Resistant Hepatitis B Clinical Case Anna S. F. Lok University of Michigan Ann Arbor, MI, USA.
Case study: Chronic HBV infection Marion Peters University of California San Francisco 2009.
How to prevent, diagnose and overcome resistance to nucleoside analogs ? Fabien Zoulim Liver department, Hôtel Dieu Hospital & Hepatitis research laboratory,
P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
M1M2M3M4M5M6 M10 M20 M30 M40 M50 M M1M2M3M4M5M6.
Stephanos HADZIYANNIS. Following HBeAg seroconversion a proportion of patients retains or redevelops significant HBV replication associated with persistent.
3 rd Paris Hepatitis Conference January, 20th 2009 How to optimize the management of my HBeAg negative patients? Pietro Lampertico 1st Gastroenterology.
Clinicaloptions.com/hepatitis Serum HBsAg as a Predictor of Response to PegIFN in HBeAg-Positive Patients Slideset on: Chan HL, Wong VW, Chim AM, Chan.
Hepatitis B: A Crash Course Yu-Ming Chang October 21, 2014.
Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.
Yves BENHAMOU. Management of Patients with HIV/HBV Co-infection Yves Benhamou Hepatology Department Groupe Hospitalier Pitié Salpétrière Paris, France.
Gui-Qiang Wang Department of Infectious Diseases
The Romans used the letters for numbers. I lI Ill.
Surrogate Endpoints for Hepatitis B Trials Greg Soon, Ph.D Rafia Bhore, Ph.D. Division of Biometrics III/Antiviral 8/7/2002 AC.
PLATFORMS. % PENETRATION BY AGE (MONTHLY REACH) GB adults 15+ Source: NRS PADD: NRS October 2014 – September 2015 & comScore September 2015.
Milan J. Sonneveld,1 Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry.
On-treatment management for chronic hepatitis B (CHB) in patients receiving oral antiviral therapy Byung-Ho Kim Kyung Hee University School of Medicine.
Copyright 2007 The ACT-HBV Korea & UMT. All Rights Reserved 강동 경희대병원 소화기내과 이 정일 만성 B 형 간염의 치료.
Entecavir Superior to Lamivudine for Treatment of Nucleoside-Naive, HBeAg- Negative Patients Slideset on: Lai CL, Shouval D, Lok AS, et al. Entecavir versus.
Jung Min Lee, Sang Hoon Ahn, Hyon Suk Kim, Hana Park, Hye Young Chang, Do Young Kim, Seong Gyu Hwang, Kyu Sung Rim, Chae Yoon Chon, Kwang-Hyub Han, and.
HBV DNA Quantification: Results from the UK NEQAS Proficiency Panel
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Copyright © 2016 McGraw-Hill Education. All rights reserved.
A logcopies/ml b IU/ml HBV DNA levels ALT levels Figure S1.
Acute HCV genotype 1 infection * No HBV or HIV co-infection
Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen–Positive Chronic Hepatitis B Patients  Grace Lai–Hung Wong, Vincent Wai–Sun.
Volume 139, Issue 2, Pages (August 2010)
Results of Recent EQA Panels for Blood Borne Viruses
Nefrologia dei trapianti
Volume 67, Issue 2, Pages (August 2017)
Lamivudine + INF - a At each visit: clinical examination, transaminase
How to optimize the management of my HBeAg negative patients?
Volume 139, Issue 6, Pages (December 2010)
Volume 141, Issue 4, Pages (October 2011)
Volume 146, Issue 5, Pages (May 2014)
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update  Emmet B. Keeffe, Douglas T. Dieterich,
Accuracy of International Guidelines for Identifying Significant Fibrosis in Hepatitis B e Antigen–Negative Patients With Chronic Hepatitis  Faisal M.
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions 
Volume 142, Issue 5, Pages e3 (May 2012)
Suna Yapali, Nizar Talaat, Anna S. Lok 
Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen–Positive Chronic Hepatitis B Patients  Grace Lai–Hung Wong, Vincent Wai–Sun.
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Volume 143, Issue 3, Pages (September 2012)
Volume 50, Issue 4, Pages (April 2009)
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Volume 130, Issue 7, Pages (June 2006)
Volume 139, Issue 4, Pages e3 (October 2010)
April May April May June July July June August Sept August
Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection  Hong Shen, Mazen Alsatie, George Eckert, Naga Chalasani, Lawrence.
Volume 139, Issue 2, Pages (August 2010)
Chronic Hepatitis B: Current Testing Strategies
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China  Y. Zhang,
Volume 126, Issue 1, Pages (January 2004)
Volume 44, Issue 2, Pages (February 2006)
Scott J. Cotler, Manish K. Dhamija, Fabiolla Siqueira, Anna H
Hepatitis B Immunoglobulin and Lamivudine Improve Hepatitis B–Related Outcomes After Liver Transplantation: Meta-Analysis  Rohit Loomba, Ayana K. Rowley,
Volume 132, Issue 7, Pages (June 2007)
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update  Emmet B. Keeffe, Douglas T. Dieterich,
Volume 141, Issue 4, Pages e2 (October 2011)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients  H.-Y. Pan, H.-Y. Pan,
This Month in Gastroenterology
Clinical Gastroenterology and Hepatology
Volume 137, Issue 6, Pages (December 2009)
Figure:
Emmet B. Keeffe, Douglas T
Volume 125, Issue 6, Pages (December 2003)
--- 6-months’ therapy months’ therapy Supplementary Figure 1.
Presentation transcript:

Figure 1A ADV ADV+LAM HBV DNA (Log IU/mL) ALT (IU/mL) A Months of therapy M0M7M14M21M28M35M42M48M56

Figure 1B ADV ADV+LAM HBV DNA (Log IU/mL) ALT (IU/mL) B Months of therapy M0M5M10M15M20M25M30M35M40M45

Figure 1C ADV HBV DNA (Log IU/mL) ALT (IU/mL) C Months of therapy M0M5M10M15M20M25M30M35M40M45

Figure 1D ADV HBV DNA (Log IU/mL) ALT (IU/mL) D Months of therapy M0M5M10M15M20M25

Figure 1E E ADV ADV + LAM HBV DNA (Log IU/mL ) ALT (IU/mL) Months of therapy M0M7M14M21M28M35M42

Figure 1F F ADV HBV DNA (Log IU/mL) ALT (IU/mL) Months of therapy M0M10M20M30M40M50

Figure 1G G ADV ADV+LAM HBV DNA (Log IU/mL) ALT (IU/mL) Months of therapy M0M7M14M21M28M35M42M48